10 year coronary heart disease (CHD) risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer (EBC) patients taking aromatase inhibitors (AI)
Study identifier:NIS-OKR-DUM-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors
Medical condition
Breast Cancer
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Female
Actual Enrollment
1114
Study type
Observational
Age
50 Years +
Date
Study Start Date: 01 May 2009
Primary Completion Date: 01 Mar 2010
Study Completion Date: 01 Mar 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
JoonWoo Bahn
AstraZeneca Korea
